Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

By sjmartinez • March 7, 2025

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study. Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07656-z. Epub ahead of print. PMID: 40050524.

Tags: breast cancer, event-free survival, GnRHa, Gonadotropin-releasing hormone agonists, Goserelin, Hematology/Oncology, Premenopausal, Publications, real-world evidence

Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]

Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer

Alkassis S, Suresh Y, Lipsyc-Sharf M, Zhang S, Gianni C, Medford A, Bardia A, Ashouri S, Kapoor N. Circulating tumor DNA detection of local recurrence[...]

Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration

Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah[...]